Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
- MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control
- Phase 1b ‘MTX325-101’ study – taking place in UK, Europe and Australia – will assess MTX325’s clinical proof-of-mechanism, safety and tolerability in 36 patients with mild to moderate Parkinson’s disease
- Comes after successful completion of Phase 1a study of MTX325 in healthy volunteers
CAMBRIDGE, UK, 15 October 2026 – Mission Therapeutics Limited (“Mission”), a clinical-stage biotechnology company discovering and developing novel therapeutics to restore cellular health and function by promoting the removal of dysfunctional mitochondria, today announced the first patient has been dosed in its Phase 1b proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD). The patient was dosed at the Royal Liverpool University Hospital in the UK.
